Abstract
Treatment options for hormone-dependent advanced breast cancer (BC) have evolved from surgical oophorectomy, first proposed over a century ago. The discovery of steroid hormones, steroid hormone receptors and the concept that inhibition of steroid biosynthesis or hormone receptor blockade prevents tumor growth, have been introduced and tested clinically. Today, the aromatase inhibitors are the current standard of care for metastatic hormone-sensitive BC in postmenopausal women. To get to this point, many others drugs have been investigated in the continuing search for improved treatment of advanced BC. Agents as high dose estrogens, progestins, antiprogestins, androgens and somatostatin analogues were tested time ago and novel and promising agents, as fulvestrant or sulfatase inhibitors are currently going through a comprehensive clinical trial program. By reviewing the clinical data on the endocrine therapy of advanced BC, we project those areas of future clinical research, beyond the well-known and established tamoxifen and aromatase inhibitors.
Keywords: Fulvestrant, progestins antagonists, estrogens, androgens, megestrol acetate, sulfatase inhibitor
Current Cancer Therapy Reviews
Title: Endocrine Therapy for Advanced Breast Cancer: Beyond Tamoxifen and Aromatase Inhibitors
Volume: 6 Issue: 1
Author(s): Angel Guerrero-Zotano and Franco Muggia
Affiliation:
Keywords: Fulvestrant, progestins antagonists, estrogens, androgens, megestrol acetate, sulfatase inhibitor
Abstract: Treatment options for hormone-dependent advanced breast cancer (BC) have evolved from surgical oophorectomy, first proposed over a century ago. The discovery of steroid hormones, steroid hormone receptors and the concept that inhibition of steroid biosynthesis or hormone receptor blockade prevents tumor growth, have been introduced and tested clinically. Today, the aromatase inhibitors are the current standard of care for metastatic hormone-sensitive BC in postmenopausal women. To get to this point, many others drugs have been investigated in the continuing search for improved treatment of advanced BC. Agents as high dose estrogens, progestins, antiprogestins, androgens and somatostatin analogues were tested time ago and novel and promising agents, as fulvestrant or sulfatase inhibitors are currently going through a comprehensive clinical trial program. By reviewing the clinical data on the endocrine therapy of advanced BC, we project those areas of future clinical research, beyond the well-known and established tamoxifen and aromatase inhibitors.
Export Options
About this article
Cite this article as:
Guerrero-Zotano Angel and Muggia Franco, Endocrine Therapy for Advanced Breast Cancer: Beyond Tamoxifen and Aromatase Inhibitors, Current Cancer Therapy Reviews 2010; 6 (1) . https://dx.doi.org/10.2174/157339410790596498
DOI https://dx.doi.org/10.2174/157339410790596498 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pharmacokinetic Interactions Between Herbal Medicines and Prescribed Drugs: Focus on Drug Metabolic Enzymes and Transporters
Current Drug Metabolism LncRNA as a Therapeutic Target for Angiogenesis
Current Topics in Medicinal Chemistry Dysregulation of LncRNAs in Placenta and Pathogenesis of Preeclampsia
Current Drug Targets In Silico Studies in Drug Research Against Neurodegenerative Diseases
Current Neuropharmacology DNA Fragmentation, Cell Cycle Arrest, and Docking Study of Novel Bis Spiro-cyclic 2-oxindole of Pyrimido[4,5-b]quinoline-4,6-dione Derivatives Against Breast Carcinoma
Current Cancer Drug Targets Drug Targeting Systems for Cancer Therapy: Nanotechnological Approach
Mini-Reviews in Medicinal Chemistry Synthesis and Anticancer Activities of New Benzothiadiazinyl Hydrazinecarboxamides and Anilino[1,2,4]triazolo[1,5-b][1,2,4]thiadiazine 5,5-diones
Medicinal Chemistry Multiple Sclerosis, Gut Microbiota and Permeability: Role of Tryptophan Catabolites, Depression and the Driving Down of Local Melatonin
Current Pharmaceutical Design The Chemokine System as a Therapeutic Target in Autoimmune Thyroid Diseases: A Focus on the Interferon-γ Inducible Chemokines and their Receptor
Current Pharmaceutical Design Proinflammatory Cytokines in Breast Cancer: Mechanisms of Action and Potential Targets for Therapeutics
Current Drug Targets Ruthenium Antimetastatic Agents
Current Topics in Medicinal Chemistry Xenobiotic Metabolising Enzymes: Impact on Pathologic Conditions, Drug Interactions and Drug Design
Current Topics in Medicinal Chemistry The Relationship Between Oncogene Expression and Clinical Outcome in Endometrial Carcinoma
Current Cancer Drug Targets Targeting Rho GTPases by Peptidic Structures
Current Pharmaceutical Design Signaling Molecules: The Pathogenic Role of the IL-6/STAT-3 Trans Signaling Pathway in Intestinal Inflammation and in Colonic Cancer
Current Drug Targets Estrogen, A Double-Edged Sword: Modulation of TH1- and TH2-Mediated Inflammations by Differential Regulation of TH1 / TH2 Cytokine Production
Current Drug Targets - Inflammation & Allergy Production of Retroviral Vectors: Review
Current Gene Therapy The Immunological Side-Effects of Sedative Agents in the Intensive Care Unit
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Resveratrol Inhibits the Epithelial-Mesenchymal Transition of Pancreatic Cancer Cells Via Suppression of the PI-3K/Akt/NF-κB Pathway
Current Medicinal Chemistry Multi-Targeted Agents in Cancer Cell Chemosensitization: What We Learnt from Curcumin Thus Far
Recent Patents on Anti-Cancer Drug Discovery